|
|
|
|
Thermogenesis Holdings Inc (THMO) |
|
Price: $1.2050
$0.04 
2.991%
|
| Day's High:
| $1.24
| Week Perf:
| 0.42 %
|
| Day's Low: |
$ 1.17 |
30 Day Perf: |
-3.6 % |
| Volume (M): |
30 |
52 Wk High: |
$ 6.67 |
| Volume (M$): |
$ 36 |
52 Wk Avg: |
$1.71 |
| Open: |
$1.17 |
52 Wk Low: |
$0.08 |
|
|
| Market Capitalization (Millions $) |
3 |
| Shares
Outstanding (Millions) |
2 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
9 |
| Net Income (TTM) (Millions $) |
-15 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
2 |
Thermogenesis Holdings Inc
Company Address: 2711 Citrus Road Rancho Cordova 95742 CA
Company Phone Number: 858-5100 Stock Exchange / Ticker: NASDAQ THMO
| THMO is expected to report next financial results on November 09, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Kewaunee Scientific Corporation
Kewaunee Scientific Corporation, a prominent Laboratory Analytical Instruments company, recently released its financial results for the fiscal first quarter of 2024. Despite a decline in revenue, the company managed to achieve profitability, indicating certain positive developments for shareholders. This article will analyze the financial results and examine how they may impact the company's future.
1. Revenue Decline:
Kewaunee Scientific Corporation experienced a decrease in revenue by -2.412% to $48.91 million compared to the previous year. This decline can pose challenges, as it signifies a potential slowdown in sales growth. However, it is essential to consider the reasons behind the drop in revenue, aiming to identify any temporary or fixable issues affecting Kewaunee's performance.
|
|
Agilent Technologies Inc
Agilent Technologies Inc. experienced a modest increase in its stock price over the last five trading days, rising by 1.16%. However, this gain must be put into perspective, as the year-to-date performance of the stock is at -19.31%. Investors should evaluate this recent uptick in light of the overall downward trend in the company's stock value.
One of the contributing factors to this decline is a reduction in earnings per share. Agilent Technologies Inc. saw a significant decrease of -65.45% in earnings per share, falling to $0.38. Additionally, the company witnessed a revenue decrease of -2.678% to $1.67 billion compared to the previous fiscal period.
|
|
Pressure Biosciences Inc
Pressure Biosciences Inc's (PBIO) financial results for the second quarter of 2023 have left analysts and investors with mixed emotions. While the company reported a surge in net deficit and a decline in inventories and accounts receivable, they managed to achieve modest revenue growth. This article will analyze PBIO's financial performance in the context of the overall Laboratory Analytical Instruments industry and the company's stock performance.
Financial Results Analysis:
PBIO reported a per-share deficit of $-0.57 for the second quarter of 2023, an increase from -$0.32 in the same quarter a year ago. Sequentially, the deficit also rose from -$0.46 per share from the prior quarter. This decline in profitability raises concerns among investors and underscores the need for PBIO to address its financial challenges.
|
|
Accelerate Diagnostics Inc
Accelerate Diagnostics Inc (AXDX) has reported an increase in losses for the fiscal time-frame ending June 30, 2023, primarily due to weak demand. The net loss per share advanced to $-2.97 from $-0.24, indicating a significant decline in profitability. Additionally, the company's revenue witnessed a decline of 27.506%, amounting to $2.80 million compared to $3.86 million in the previous year.
In comparison to the previous quarter, there was a slight decrease in revenue by 0.462%, from $2.81 million. Furthermore, there was a surge in loss per share from $-0.17. These figures highlight the ongoing struggles faced by Accelerate Diagnostics Inc in maintaining a stable financial performance.
For the financial time-frame ending June 30, 2023, Accelerate Diagnostics Inc recorded a net loss of $-32.735 million, surpassing the loss of $-18.523 million reported a year ago. This reflects a continuing trend of declining profitability for the company.
|
|
Phenomex Inc
Phenomex Inc, a company specializing in [insert industry/sector], recently released its financial results for the second quarter of 2023. The report showcases weak business performance, resulting in a rise in losses. This article aims to interpret the financial results, highlighting the implications they may have on Phenomex Inc's future prospects.
1. Substantial Losses:
The second quarter saw an increase in losses, with the shortfall per share rising from $-0.38 to $-0.51. This signals a concerning trend that the company needs to address promptly.
|
| Per Share |
Current |
| Earnings (TTM) |
-5.33 $ |
| Revenues (TTM) |
3.56 $
|
| Cash Flow (TTM) |
0.18 $ |
| Cash |
1.79 $
|
| Book Value |
1.06 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-5.33 $
|
| Revenues (TTM) |
3.56 $ |
| Cash Flow (TTM) |
0.18 $ |
| Cash |
1.79 $
|
| Book Value |
1.06 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2023 CSIMarket, Inc. All rights
reserved. This site uses cookies to make your browsing experince better. By
using this site, you agree to the Terms of Service and Privacy Policy - UPDATED
(Read about our Privacy Policy)
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
